bioAffinity Technologies Executes Agreement with Fosun Long March to Evaluate CyPath® Lung for Comme
Search jobs 04-Feb-2021 bioAffinity Technologies Executes Agreement with Fosun Long March to Evaluate CyPath® Lung for Commercialization in China China’s leading healthcare company to evaluate bioAffinity’s non-invasive, highly accurate test for early-stage lung cancer with aim to commercialize in world’s largest market SAN ANTONIO--(BUSINESS WIRE)--#TCPP--Shanghai Fosun Long March Medical Science Co., Ltd. (Fosun Long March) has executed a non-binding Letter of Intent (LOI) with bioAffinity Technologies, Inc. providing for Fosun to evaluate...
Source: pharmiweb.com